Iterative Health Raises $150M Series B to Transform GI Care and Colorectal Cancer Screening

Iterative Health is thrilled to announce a major milestone that further accelerates our mission to empower exceptional gastrointestinal care: we have successfully raised $150,000,000 in funding through Iterative Scopes.

This transformative infusion of capital will be strategically invested to enhance our state-of-the-art healthcare technology and services while expanding our research capabilities, particularly in the realm of artificial intelligence and clinical research.

Based in Cambridge, Massachusetts, and supported by robust operations across the United States, Iterative Health is uniquely positioned at the forefront of revolutionizing colorectal cancer screenings and clinical research.

Our commitment to providing healthcare professionals with advanced tools and reliable data insights is driven by a continual pursuit of innovation that not only ensures high-quality screenings but also expands patient access to promising novel therapeutics.

With this new funding, we aim to further optimize our technology platforms, broaden our clinical research collaborations, and extend our support to study sponsors and healthcare providers nationwide.

We are excited about the potential to set new industry benchmarks and make significant strides in improving patient outcomes.

In the midst of these exciting developments, we also want to remind our community to exercise caution—there have been recent attempts to impersonate members of our team.

If you ever have any doubt about whether you are receiving a genuine message or connection from Iterative Health, please do not hesitate to reach out directly via our official LinkedIn page or our website.

This measure ensures that our valued partners always receive accurate and secure communications from our team.